Investigations into the efficacy of a novel extubation-aerosol shield: a cough model study

Gen Hasegawa, Wataru Sakai, Tomohiro Chaki, Shunsuke Tachibana, Atsushi Kokita, Takenori Kato, Hidekazu Nishimura, Michiaki Yamakage

Department of Anaesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan
Kato Koken, Isehara, Japan
Virus Research Centre, Clinical Research Division, Sendai Medical Centre, Sendai, Japan

SUMMARY

Background: Physicians have had to perform numerous extubation procedures during the prolonged coronavirus disease 2019 (COVID-19) pandemic. Future pandemics caused by unknown pathogens may also present a risk of exposure to infectious droplets and aerosols.

Aim: This study evaluated the ability of a newly developed aerosol barrier, "Extubation-Aerosol (EA)-Shield" to provide maximum protection from aerosol exposure during extubation via an aerosolised particle count and high-quality visualisation assessments.

Methods: We employed a cough model having parameters similar to humans and used micron oil aerosol as well as titanium dioxide as aerosol tracers. Aerosol barrier techniques employing a face mask (group M) and EA-Shield (group H) were compared.

Findings: The primary outcome was the difference in the number of particles contacting the physician's face before and after extubation. The maximum distances of aerosol dispersal after extubation were measured as the secondary outcomes. All aerosolised particles of the two tracers were significantly smaller in group H than in group M (p < 0.05). In addition, the sagittal and axial maximum distances and sagittal areas of aerosol dispersal for 3, 5, and 10 s after extubation were significantly smaller in group H than in group M (p < 0.05).

Conclusion: This model indicates that EA-Shield could be highly effective in reducing aerosol exposure during extubation. Therefore, we recommend using it as an aerosol barrier when an infectious aerosol risk is suspected.

Introduction

Physicians must pay attention to droplet and aerosol exposure not only during intubation but also during extubation, which is a droplet and aerosol-generating procedure [1]. During a prolonged pandemic, such as that caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus,
physicians have to perform numerous extubation procedures that have a risk of infectious droplet and aerosol exposure. SARS-CoV-2 can be transmitted even by asymptomatic people through droplets and aerosols, and personal protective equipment (PPE) cannot completely protect against their spread [2,3]. Anaesthetists and intensivists are at low risk of SARS-CoV-2 infection, possibly due to well-ventilated working environment and the use of high-performance PPE [4]. However, in reality, aerosol procedures must be performed without sufficient air conditioning and PPE, when the distance between hospital beds is insufficient. Protection against viral infections during intubation, outside of a well-equipped environment has not yet been established. Pathogens including SARS-CoV-2, SARS-CoV, and influenza virus can be transmitted during aerosol-generating procedures [5]. Mass-producible and single-use aerosol barriers are needed during aerosol-generating procedures when there is a shortage of protective equipment. Several guidelines do not provide clear evidence of using aerosol barriers to protect against droplet infections during extubation [6–8]. Although several aerosol barriers have been developed for use, during these procedures [9–13], they have not been fully tested to check the dispersal of aerosol particles of a size that would allow them to remain infectious. Although one guideline has recommended using a face mask as an aerosol barrier during extubation [14], its effectiveness against aerosol protection is unclear. However, the dispersal of aerosols cannot be perceived visually by the naked eye. Protective methods need to be based on evidence of aerosol dispersal. Moreover, it is necessary to establish a safer method of extubation that can be performed under adverse conditions, including inadequate air conditioning and insufficient PPE.

We have developed an aerosol barrier termed “Extubation-Aerosol (EA)-Shield” (Figure 1) to protect physicians and medical staff against aerosol exposure during extubation. The barrier is mass-producible at a low cost and can be manufactured and used in developing countries. With the EA-Shield, emergency airway management after extubation, including mask ventilation and oral suctioning, can be performed without modification.

This study assessed the ability of EA-Shield to provide effective protection against aerosol exposure during extubation that was performed using aerosolised particle counting and high-quality visualisation techniques.

**Materials and methods**

**Study design**

This study did not involve human subjects as well as patient consent or the approval of internal review boards. This was an analytical and observational in vitro study.

**EA-Shield**

The EA-Shield can be made from a common 120-L plastic bag (1 m × 1.2 m), with all edges closed (Figure 1A, C–F, Video S1). The EA-Shield has one large elliptical hole on the lower layer (patient’s side) and four small holes with double-sided tape on the upper layer for each face mask, endotracheal tube, oral suction tube, and nasogastric tube. It was designed such that after extubation, the airway can be secured with a face mask through the slit in the shield, and suction can be performed with a suction tube.

Supplementary data related to this article can be found at https://doi.org/10.1016/j.infipip.2021.100193.

**Environment and procedures**

All experiments and calculations were performed after confirming adequate ventilation in the laboratory. Before each experiment, the number of atmospheric particles was determined using an airborne particle counter (PB-306, Airy Technology Japan Ltd, Kanagawa, Japan) and checked within the acceptable range of standard values according to our preliminary data (Table S1).

A high-fidelity AirSim Patient Simulator (Trucorp, Belfast, Northern Ireland), generated from the computed tomography scan of a human subject (65-year-old Caucasian, weight 62 kg), was used (Figure 1B). In addition, an air blower (Air blower, Kato Koken) and a cough simulator, and the vinyl chloride pipe connecting the trachea of the mannequin to this air blower was surrounded by clay to prevent air leakage, thereby strengthening it against the jet pressure of the cough simulator. The air blower was adjusted to create cough patterns resembling those of humans (Table S1).

We used titanium dioxide (Tree of Life, Tokyo, Japan) and micron oil aerosol (Kato Koken) as the aerosol model and tracer, respectively. Titanium dioxide as an aerosol has a wide range of particle sizes (0.07–11 μm, D50 = 3.92 μm), that were measured with a particle counting device (LA-950, Horiba, Kyoto, Japan). Micron oil aerosol (D50 = 10 μm), generated by PS-2006 (Dainichi, Niigata, Japan), has been used for visualisation experiments in the field of fluid mechanics owing to its ability to track airflow. In each experiment, titanium dioxide (0.25 g) and micron oil aerosol (300 ml) were placed into the mouth of the patient simulator without leakage, before firing the air blower. Before each procedure, the mannequin was cleaned from inside with an air blower to remove any remaining tracers.

The intake port of an airborne particle counter (PB-306) was positioned just beside the head of the physician at head height (75 cm above the head of the simulated patient). This device counts airborne particles with sizes of 0.3, 0.5, 1.0, 2.5, 5.0, and 10 μm, for 1 min. The flow rate of our airborne particle counter was 2.83 l/min, with detection of ambient air occurring in 1 s sweeps.

We used two types of light sources: white LED light (wavelength, 430–700 nm; 90 W) (Kato Koken) to assess the spatial aerosol spread and a thin green laser light sheet generated by a YVO4 laser (wavelength, 532 nm; 2,000 mW) (Kato Koken) to assess the sagittal and transverse aerosol spread from the mannequin’s mouth and to measure the hydrodynamic outcomes. All coughing jet plume images were captured by a camera specialised for visualising fine particles (PV2, Kato Koken) with an optical resolution of 2,048 × 1,536 pixels per video frame. The maximum speed was 120 fps. All particle image velocimetry system images were captured using a high-speed camera (Kato Koken) with an optical resolution of 640 × 480 pixels per video frame. The maximum video frame speed was 8,000 fps.

The white LED light was placed 2 m caudal to the mouth of the mannequin. Video cameras were placed on the side and 45° diagonally upwards. The green slit-sheet light and video
camera were placed orthogonally. To prevent reflection of light that could lead to errors in the video graphic measurements, the physician dressed completely in black, and the mannequin was painted black by a professional painting company (Ihara Paint, Hokkaido, Japan). The image analysis was based on the principle that the intensity of the scattered light is proportional to the particle concentration. The area of scattered particles illuminated with the green slit-sheet light was recorded and analysed using image software (Particle Viewer, Kato Koken, Japan). The reference area was set at $2,048 \times 1,536$ pixels to $136.7 \times 102.4$ cm.

We placed an 8.0-mm tube (Hi-Contour Oral/Nasal Tracheal Tube Cuffed; Covidien, Dublin, OH) into the trachea of the mannequin and fixed it at a depth of 22 cm in the right corner of the mouth. The timing of extubation was defined as the withdrawal of the endotracheal tube from the corner of the mouth to a depth of 16 cm and the position of the glottis. The firing from the air blower was synchronised with the moment of extubation, to ensure a constant timing of the simulated cough during all experiments.

**Aerosol barrier during extubation**

Two different aerosol barrier techniques were used during extubation:

i) Mask-over-tube extubation technique (face mask method: group M) [10].

In this method, the tracheal tube was extubated while using the face mask to prevent aerosol dispersal caused by the patient’s cough. This technique is recommended in published guidelines as an effective aerosol barrier method [14].
ii) Extubation with EA-Shield (Hasegawa method: Group H)

The Hasegawa method requires only an EA-Shield. The details of the Hasegawa method are presented in Table SI.

Study outcomes

The primary outcome was the difference in the number of particles before and after extubation as aerosol exposure to the physician. The baseline values are listed in Table SII. In addition, the following secondary outcomes were verified using high-quality video images during extubation.

i) Sagittal and axial distances of aerosol spread in videography taken from the mannequin’s side with the green laser sheet for 3, 5, and 10 s after the air blower fired. ii) Sagittal area of aerosol spread in videography taken from in front of the mannequin with the green laser sheet, for 3, 5, and 10 s after the air blower fired. iii) Vectors of aerosol spread in videography were taken from the mannequin’s side using a green laser sheet. Titanium dioxide was used as a tracer to measure secondary outcomes.

Figure 2. Summary of particle counting for micron oil aerosol and titanium dioxide. All micron oil aerosol and titanium dioxide particles were significantly smaller in group H than in group M. (I) Results of particle counting for micron oil aerosol. (II) Results of particle counting for titanium dioxide. Particles with diameters of (a) 0.3 \( \mu \)m, (b) 0.5 \( \mu \)m, (c) 1.0 \( \mu \)m, (d) 2.5 \( \mu \)m, (e) 5.0 \( \mu \)m, and (f) 10 \( \mu \)m. * \( p < 0.05 \).
**Statistical analysis**

The Shapiro-Wilk test was used to determine whether the data were normally distributed. Normally distributed variables are shown as the mean (SD), and non-normally distributed data are shown as median and interquartile range (IQR). Data were analysed using the unpaired t-test or Mann-Whitney U test. Statistical significance was set at \( p < 0.05 \). All statistical analyses for this study were performed using GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA). Vector analysis was performed using software FlowExpert2D2C (Kato Koken, Isahara, Japan).

According to our preliminary study of total particle counts, \( \Delta = 3,658,720 \) and \( \text{SD} = 1,946,610 \) represented significant differences (Table SIII). Sample sizes were calculated using R version 3.5.3, with \( \alpha = 0.05 \), and \( 1—\beta = 0.8 \), revealing that five samples were required in each group.

**Results**

All aerosolised particles of micron oil aerosol and titanium dioxide were significantly smaller in group H than in group M. The sizes of all aerosolised particles of both tracers in group H were within the baseline range. A summary of the primary outcomes is shown in Figure 2 and Tables SIV and SV.

Sagittal maximum distances of aerosol dispersal at 3, 5, and 10 s after the cough simulation were significantly smaller in group H than in group M. The axial maximum distances of aerosol dispersal for 3, 5, and 10 s after the cough simulation were also smaller in group H than in group M. The results of the sagittal and axial maximum distances of aerosol dispersal are presented in Table I.

| Table I Results of particle imaging velocimetry |
|-----------------------------------------------|
| Time after the cough | Group M (n=5) | Group H (n=5) | Hodges-Lehmann estimator | 95% confidence interval | P-value |
|----------------------|---------------|---------------|--------------------------|------------------------|---------|
| **Sagittal Maximum Distance** | | | | | |
| 3 s (mm) | 472 [445 to 488] | 0 [0 to 0] | 472 | 228 to 494 | 0.008 |
| 5 s (mm) | 527 [521 to 620] | 0 [0 to 0] | 527 | 192 to 652 | 0.008 |
| 10 s (mm) | 888 [744 to 895] | 0 [0 to 0] | 888 | 570 to 964 | 0.008 |
| **Axial Maximum Distance** | | | | | |
| 3 s (mm) | 418 [415 to 438] | 0 [0 to 0] | 418 | 353 to 443 | 0.008 |
| 5 s (mm) | 430 [408 to 486] | 0 [0 to 0] | 430 | 307 to 511 | 0.008 |
| 10 s (mm) | 572 [507 to 637] | 0 [0 to 0] | 572 | 506 to 648 | 0.008 |
| **Sagittal Maximum Area** | | | | | |
| 3 s (mm²) | 9170 [4388 to 9568] | 0.894 [0.894 to 2.235] | 9567 | 4387 to 149695 | 0.011 |
| 5 s (mm²) | 12772 [7431 to 13638] | 1.788 [1.788 to 5.812] | 13633 | 7429 to 22129 | 0.012 |
| 10 s (mm²) | 22080 [6894 to 22244] | 1.788 [1.788 to 1.789] | 22078 | 4712 to 55419 | 0.011 |
| **Maximum velocity of aerosol dispersal during extubation** | | | | | |
| Group M (n=5) | 12.7 (1.72) | NA | | | |

Sagittal and axial maximal distances and sagittal maximum areas 3, 5, and 10 s after the cough simulation and the maximum velocity of wind around the face of the mannequin were determined using a particle imaging velocimetry system. In group H, all sagittal and axial maximum distances were zero, but the maximum area in this group was not zero because some aerosolised particles were observed within the baseline range in the experimental room. The sagittal and axial maximum distances and sagittal maximum areas in group H were significantly smaller than those in group M. The axial maximum area could not be assessed because of the light reflection. In group H, wind was not observed around the face of the mannequin; therefore, maximum velocity could not be detected using the particle image velocimetry system. In group M, the wind speed around the face of the mannequin was higher than the cough speed (10 m/s) around the mouth of the mannequin because of the acceleration of wind speed in the space between the face mask and the face of the mannequin.
emerged from the space between the face mask and the face of
the mannequin in the straight right direction. A summary of the
results is presented in Figure 5 and Table I.

Discussion

The results of particle counting and the distance and area of
aerosol dispersal in group H were all within the baseline range,
indicating that EA-Shield could significantly prevent exposure
of the physician to the aerosol particles (0.3\text{-}10 \, \mu\text{m} in size).
These important results were supported by high-quality video-
egraphy. The results of particle image velocimetry revealed
that EA-Shield could also prevent wind generation as a result of
coughing, during extubation. The present findings suggest that
EA-Shield could prevent the exposure of aerosol to physicians
and medical staff.

An infection barrier must be cheap, mass-producible, and
single-use. EA-Shield has all these characteristics because it
can be made using a 120-l clear plastic bag and double-sided
tape. Our experiment was performed even in a non-negative
pressurised room, and the results revealed that EA-Shield
could provide protection against aerosols in non-negative
pressurised rooms, including patient wards, operating
rooms, and intensive care units. By using the EA-Shield,
emergency airway management after extubation, including
mask ventilation and oral suctioning, can be performed
without modification. In clinical practice, it can be adapted to
the patient’s body movements. Moreover, this shield was
designed to allow effective ventilation inside using a fixed
suction tube that creates a continuous negative pressure
during the procedure (Video S1). After the patient’s cough had
subsided, he was made to wear a mask before the shield was
removed. However, we believe that it is better to wear PPE
because the Hasegawa method needs to be validated in clin-
cal practice and has not been tested for exposure during
discarding.

Although particle counting can provide numerical and
objective assessment, it provides fixed-point observations,
because spatial assessment is not sufficient [15\text{-}17]. The vol-
ume aspirated during the measurement is small compared to
space or ventilation, and particle counting is inevitably influ-
enced by the direction of the inlet. Although visualisation
assessments can easily determine the spatial and temporal
dispersal of aerosols, it is difficult to obtain numerical and
objective assessments from videography [18\text{-}20]. To provide a
thorough evaluation of aerosol dispersal, we combined particle
counting with these assessments.

In addition, we used two types of tracers. Titanium
dioxide particles have a wide range of diameters [21,22],
whereas micron oil has good flowability for air movement
[18\text{-}20]. The aerosol particles have a wide range of diame-
ters (0.01\text{-}100 \, \mu\text{m}); therefore, it is difficult to assess the
dispersal of these particles of all sizes, at once. Therefore,
we measured the wind vector with micron oil, which has good
tracking of air movement [23\text{-}25]. Measurement of the wind

Figure 3. Photography of aerosol dispersal at 3, 5, and 10 s after the cough simulation with white LED light and green slit-sheet light
in group M. (I) Photography with white LED light (three-dimensional assessments), (II) photography with green slit-sheet light in a sagittal
view, and (III) photography with green slit-sheet light in an axial view (two-dimensional assessment from two directions). (a) Aerosol
dispersal is shown at 3 s, (b) 5 s, and (c) 10 s after the cough simulation. Aerosol dispersal started from the right side of the mannequin
and reached the physician’s face. At 10 s after extubation, aerosolised particles had surrounded the physician’s face.
vector provided information regarding the dispersal of aerosol particles having small diameters (<0.3 μm, which are invisible with a CCD camera) [26]. Particles 0.3 μm in diameter or larger could be assessed using titanium dioxide, particle counting, and visualisation assessments. Therefore, the combination of titanium dioxide and micron oil provides information regarding the dispersal of aerosol particles of all sizes.

Our videography showed that EA-Shield could completely prevent aerosol exposure to the physician as well as in the surrounding area. It could protect the medical staff who stand by the patient as well as the instruments from aerosol exposure during extubation.

We used two-dimensional and three-dimensional high-quality videography for visualisation assessments. Our results revealed that EA-Shield completely prevented aerosol dispersal. Although small particles (>0.3 μm) can be detected using two-dimensional videography with the green slit-sheet light detects, spatial assessment is not sufficient because the laser-sheet light scatters only the particles on the laser line [18–20]. In addition, videography using a green slit-sheet laser has better quality than videography using other light sources because it is not easily affected by reflection. We used a green slit-sheet laser from two directions and assessed sagittal and axial aerosol dispersal. Measurement of the maximum distance and area of aerosol dispersal for 3, 5, and 10 s after cough simulation using green slit-sheet light could provide numerical and objective assessments [18–20].

This is the first study that assesses three-dimensional aerosol dispersal using white LED light. Three-dimensional visualisation assessment using white LED light enables more detection of spatial and temporal aerosol dispersal than two-dimensional visualisation assessment. However, because white LED light is a wide-angle strong light source, reflection must occur, and numerical assessment may be difficult. The combination of two-dimensional and three-dimensional visualisation assessments can provide numerical, spatial, and temporal information on aerosol dispersal. According to the results obtained using a particle image velocimetry system, EA-Shield could prevent the generation of wind after extubation. It is therefore possible that EA-Shield can prevent transmission of aerosols and droplets as well as particles smaller than aerosols. A particle image velocimetry system has been used to assess aerosol dispersal from cough and cough parameters in several studies [23–25]. One study showed that the wind parameter determined by using a particle image velocimetry system enabled the assessment of the dispersal of aerosol particles with particles of small diameters [27]. The present results showed that using a face mask could not prevent exposure of the physician to aerosol...
particles, during extubation. Therefore, using this method could be a mistake. The Hasegawa method is highly reproducible and can be used by anyone. The results of the vector analysis revealed that this method accelerated the wind speed of the cough. This acceleration was caused by the narrow space between the face of the mannequin and the face mask compared to the mannequin’s mouth, that could increase aerosol dispersal during extubation. Large aerosol particles (60–100 μm in diameter) have been found to be >2 m with a velocity of 10 m/s recorded at the exit point [28,29]. Using a face mask could generate dispersal of the aerosols at more than 10 m/s during extubation; therefore, the medical staff must maintain a distance of at least 2 m from the patient.

In addition, an assistant is required for the physician during extubation; therefore, the face mask method increases the number of persons who could be exposed to aerosols, which does not obey the principle of aerosol protection. Moreover, the results obtained using the present particle image velocimetry system showed that the face mask method could generate turbulence. Turbulence is buoyant, increasing the aerosol dispersal and allowing the aerosolised particles to float in the air for a long time [30]. In contrast, the EA-Shield is an aerosol barrier that does not generate turbulence during extubation.

Although we used two tracers in our experiment, the aerosol dispersal determined by our tracers would not be the same as the actual aerosol dispersal after extubation. In addition, in a clinical situation, the patient can move during extubation, and the direction of the cough and aerosol dispersal can be altered. Moreover, aerosol dispersal can be changed by environmental factors including atmospheric pressure, room wind, temperature, humidity, and room size, as well as by movement factors, including those of medical staff around the patient [31–34]. We conducted our experiment with a trained physician in a quiet room. Therefore, clinicians must consider how they can utilise the present results to obtain individual protection from aerosol dispersal.

**Conclusions**

EA-Shield, which can be crafted with common items, protects the physician against aerosol exposure during extubation. Therefore, we recommend using EA-Shield during extubation as an aerosol barrier when the risk of infectious aerosols is suspected.

**Credit author statement**

Gen Hasegawa: Conceptualization; Methodology; Data curation; Writing original draft.
Wataru Sakai: Conceptualization; Methodology; Data curation; Writing original draft.
Tomohiro Chaki: Validation; Formal analysis; Writing review and editing.
Shunsuke Tachibana: Validation; Formal analysis; Writing review and editing.
Atsushi Kokita: Conceptualization; Methodology; Data curation.
Takenori Kato: Data curation; Visualization; Supervision.
Hidekazu Nishimura: Writing review and editing.
Michiaki Yamakage: Writing review and editing; Supervision; Funding acquisition.

**Acknowledgements**

We would like to thank Kouya Mikami of Kato Koken, Isehara, Japan, for their help with the experiments.
Conflict of interest statement
Authors declare no conflict of interest.

Funding sources
None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.infpip.2021.100193.

References

[1] Brown J, Gregson FKA, Shrimpton A, Cook TM, Bzdek BR, Reid JP, et al. A quantitative evaluation of aerosol generation during tracheal intubation and extubation. Anaesthesia 2021;76:174–81.

[2] Yu X, Yang R. COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir Viruses 2020;14:474–5.

[3] Stewart CL, Thornblade LW, Diamond DJ, Fong Y, Melstrom LG. Personal protective equipment and COVID-19: a review for surgeons. Ann Surg 2020;272:e132–8.

[4] Cook TM, Lennane S. Occupational COVID-19 risk for anaesthesia and intensive care staff - low-risk specialties in a high-risk setting. Anaesthesia 2021;76:295–300.

[5] Smither SJ, Eastaugh LS, Findlay JS, Lever MS. Experimental aerosol survival of SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity. Emerg Microbes Infect 2020;9:1415–7.

[6] Cook TM, El-Boghdady K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus guidelines for managing the airway in patients with COVID-19: Guidelines from the Difficult Airway Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetists. Anaesthesia 2020;75:785–99.

[7] Brewster DJ, Chrimes N, Do TB, Fraser K, Groombridge CJ, Orser BA. Recommendations for endotracheal intubation of patients with COVID-19. Br J Anaesth 2020;125:e192–6.

[8] Fidler RL, Niedek CR, Teng JJ, Sturgeon ME, Zhang Q, Robinowitz DL, et al. Aerosol retention characteristics of barrier devices. Anesthesiology 2021;134:61–71.

[9] Hui DS, Hall SD, Chan MT, Chow BK, Ng SS, Gin T, et al. Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest 2007;132:540–6.

[10] Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J 2019;53:1802339.

[11] Hui DS, Hall SD, Chan MT, Chow BK, Tsou JY, Joynt GM, et al. Noninvasive positive-pressure ventilation: An experimental model to assess air and particle dispersion. Chest 2006;130:730–40.

[12] Asenjo JF. Safer intubation and extubation of patients with COVID-19. Can J Anaesth 2020;67:1276–93.

[13] Sakai W, Tachibana S, Yamakage M. Cross-holes on a plastic bag can prevent droplet spread during extubation. Anesth Analg 2020;130:1109–10.

[14] Fennelly KP. Particle sizes of infectious aerosols: implications for aerosol survival of SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity. Emerg Microbes Infect 2020;9:1415–7.

[15] Canelli R, Connor CW, Gonzalez M, Nozari A, Ortega R, Kuroki Y, Yamamoto Y. Peroral endoscopy during the COVID-19 pandemic: Efficacy of the acrylic box (Endo-Splash Protective (ESP) box) for preventing droplet transmission. JGH Open 2020;4:1224–8.

[16] Gomi K, Nagahama M, Yoshida E, Takano Y, Kuroki Y, Yamamoto Y. Peroral endoscopy during the COVID-19 pandemic: Efficacy of the acrylic box (Endo-Splash Protective (ESP) box) for preventing droplet transmission. JGH Open 2020;4:1224–8.

[17] Nishimura H, Sakata S, Kaga A. A new methodology for studying dynamics of aerosol particles in sneeze and cough using a digital high-vision, high-speed video system and vector analyses. PLOS ONE 2013;8:e80244.

[18] Wells WF. On air-borne infection: study II. Droplets and droplet nuclei. Am J Epidemiol 1934;20:611–8.

[19] Xie L, Li Y, Chwang AT, Ho PL, Seto WH. How far droplets can travel in indoor environments-revisiting the Wells evaporation-falling curve. Indoor Air 2007;17:211–25.

[20] Bourouiba L, Dehandshoewoercker E, Bush JWM. Violent respiratory events: on coughing and sneezing. J Fluid Mech 2014;745:537–63.

[21] Vuorinen V, Aarnio M, Alava M, Alopaeus V, Atanasova N, Aropainen A, et al. Modelling aerosol transport and virus exposure with numerical simulations in relation to SARS-CoV-2 transmission by inhalation indoors. Saf Sci 2020;130:104866.

[22] Tang JW, Li Y, Eames I, Chan PK, Ridgway GL. Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises. J Hosp Infect 2006;64:100–14.

[23] Elazhary MA, Derbyshire JB. Effect of temperature, relative humidity and medium on the aerosol stability of infectious bovine rhinotracheitis virus. Can J Comp Med 1979;43:158–67.

[24] Bello A, Quinn MM, Perry MJ, Milton DK. Quantitative assessment of airborne exposures generated during common cleaning tasks: a pilot study. Environ Health 2010;9:76.